Olema Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
OLMA Nasdaq 2830 olema.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Olema Pharmaceuticals, Inc.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 3rd, 2025 2:30 pm
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - May 28th, 2025 5:00 am
Olema Oncology to Participate in Upcoming Investor Conferences - May 21st, 2025 2:30 pm
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - May 21st, 2025 7:55 am
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - May 15th, 2025 5:47 am
Olema Oncology Reports First Quarter 2025 Financial and Operating Results - May 13th, 2025 2:01 pm
Olema Pharmaceuticals Says OP-3136 Molecule Shows Anti-Tumor Activity in Preclinical Models - Apr 25th, 2025 11:32 am
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 - Apr 25th, 2025 11:00 am
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet - Apr 24th, 2025 7:55 am
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) - Apr 10th, 2025 7:35 am
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting - Mar 25th, 2025 2:31 pm
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Mar 18th, 2025 2:01 pm
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference - Feb 19th, 2025 2:30 pm
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary - Feb 18th, 2025 5:00 am
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - Jan 2nd, 2025 5:00 am
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium - Dec 10th, 2024 5:00 am
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor - Dec 9th, 2024 5:00 am
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - Dec 3rd, 2024 11:37 am
Novartis and Olema expand alliance with $250m to boost breast cancer trials - Dec 3rd, 2024 7:17 am
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement - Dec 2nd, 2024 6:08 am